AKERO THERAPEUTICS
Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure, and death. The company is developing pioneering medicines designed to restore metabolic balance and halt NASH progression. Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential best-in-class treatment for NASH. The AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
AKERO THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Therapeutics
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.akerotx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
951.1 M USD
Technology used in webpage:
Google Maps IPv6 ReCAPTCHA Google Maps API COVID-19 Gravity Forms Akismet Akismet Non Hosted Akamai Hosted
Similar Organizations
Ajax Therapeutics
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
TARGAN
TARGAN is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries.
Artiva Biotherapeutics
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Lytica Therapeutics
Lytica Therapeutics, Inc. is a biotechnology company focused on developing novel peptide therapeutics.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Taiga Biotechnologies
Taiga Biotechnologies is a clinical-stage company focused on harnessing the immune system to fight infectious disease and cancer.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Akero Therapeutics
Pfizer Breakthrough Growth Initiative
Pfizer Breakthrough Growth Initiative investment in Post-IPO Equity - Akero Therapeutics
venBio Partners
venBio Partners investment in Series B - Akero Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Akero Therapeutics
LifeSci Venture Partners
LifeSci Venture Partners investment in Series B - Akero Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Akero Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series B - Akero Therapeutics
Atlas Venture
Atlas Venture investment in Series B - Akero Therapeutics
Boxer Capital
Boxer Capital investment in Series B - Akero Therapeutics
Versant Ventures
Versant Ventures investment in Series B - Akero Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-04-30 | Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer |
| 2023-01-10 | Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy |
Official Site Inspections
http://www.akerotx.com Semrush global rank: 2.11 M Semrush visits lastest month: 9.58 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Akero Therapeutics"
Akero Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like …See details»
Investors - Akero Therapeutics, Inc.
Akero Therapeutics is a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need.See details»
Akero Therapeutics - LinkedIn
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH.See details»
Akero Therapeutics Company Overview, Contact Details
Mar 5, 2024 [email protected]: 32%. See more formats. Frequently Asked Questions Where is Akero Therapeutics 's headquarters located? Akero Therapeutics 's main headquarters is …See details»
Akero Therapeutics Company Profile - Office Locations ... - Craft
Akero Therapeutics has 2 employees across 3 locations. See insights on Akero Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Akero Therapeutics | Efruxifermin (EFX) for MASH
Akero is a clinical-stage company founded to develop transformational treatments for patients with serious metabolic diseases marked by high unmet medical need.See details»
Akero Therapeutics | Efruxifermin for MASH | Leadership
Brittany de Temple is vice president of development operations at Akero. She brings more than 18 years of experience in clinical development operations including clinical operations, project management, and program strategy …See details»
Akero Therapeutics | EFX for MASH | Fc-FGF21 Fusion …
EFX currently is being evaluated in the Phase 3 SYNCHRONY program, which is composed of three clinical trials designed to support marketing applications for treatment of pre-cirrhotic MASH as well as compensated cirrhosis due to …See details»
Akero Therapeutics | Efruxifermin (EFX) for MASH | Contact
Akero Therapeutics. 601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 (650) 487-6488See details»
akerotx.com - Whois.com
Whois Lookup for akerotx.com. Login Sign up My Account Logout; Domains. Registration. Register a Domain Get your domain name now Domain Suggestions Get help picking a …See details»
Akero Therapeutics - Company Profile & Staff Directory
Akero Therapeutics is a Biotechnology company located in 601 Gateway Blvd, Suite 350, South San Francisco, California 94080, US with 45 employees. Access Akero Therapeutics's email …See details»
Akero Therapeutics (AKRO) Company Profile & Description - Stock …
Jun 20, 2019 Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is …See details»
Akero Therapeutics - Overview, News & Similar companies
Akero Therapeutics contact info: Phone number: (650) 487-6488 Website: www.akerotx.com What does Akero Therapeutics do? Akero Therapeutics is a clinical-stage company …See details»
Akero Therapeutics to Present at the BofA Securities 2025
2 days ago SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational …See details»
Press Release Details - ir.akerotx.com
2 days ago SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational …See details»
Akero Therapeutics Reports Second Quarter 2022 Financial Results …
Jun 30, 2022 EFX is also being evaluated in an expansion cohort of the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 …See details»
Akero Therapeutics Reports Recent Highlights and Third Quarter …
SAN FRANCISCO, Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with …See details»
Akero Therapeutics | EFX for MASH | Our Culture
Akero is a team of problem-solvers dedicated to pursuing bold scientific approaches to discovering and developing transformational treatments for patients with serious metabolic …See details»
Akerotx.com Domain Reputation Report - IPQS
The mail domain akerotx.com is valid, has proper DNS MX records (us-smtp-inbound-2.mimecast.com), and is able to accept new email.IPQS email validation algorithms verified …See details»
Akero Therapeutics | Efruxifermin for MASH | Clinical Trials
The 96-week Phase 2b SYMMETRY study was a multicenter, randomized, double-blind, placebo-controlled, clinical trial that enrolled 182 patients with biopsy-confirmed compensated cirrhosis …See details»